Glaukos COO Joseph E. Gilliam sells 861 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Glaukos Corp. (GKOS) President & COO Joseph E. Gilliam exercised options covering 861 shares on November 16, 2026, at exercise prices of $48.46, $55.18 and $69.30 per share, and sold 861 common shares at $250 per share. The option exercises and sale were made under a Rule 10b5-1 trading plan adopted August 13, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3, F4 | 82 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F4 | 100 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F5 | 200 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F6, F7 | 200 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F8 | 279 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 82 | $69.30 | $6K |
| Exercise | Common Stock F1 | 100 | $48.46 | $5K |
| Exercise | Common Stock F1 | 200 | $55.18 | $11K |
| Exercise | Common Stock F1 | 279 | $55.18 | $15K |
| Exercise | Common Stock F1 | 200 | $48.46 | $10K |
| Sale | Common Stock F2, F1 | 861 | $250.00 | $215K |
Footnotes (8)
- F1. Includes 40,039 restricted stock units that have not yet vested or been delivered to the Reporting Person.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
- F3. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
- F4. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
- F5. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
- F6. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
- F7. Amount reported has been adjusted to reflect a mathematical error contained in the Form 4 filed with the SEC on November 16, 2026.
- F8. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
Key Figures
Key Terms
Rule 10b5-1 trading plan financial
restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Joseph E. Gilliam's GKOS option exercise prices?
Were Joseph E. Gilliam's GKOS option exercises and sale under a trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.